Graft-versus-host disease treatment: Predictors of survival

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 12, 2010, Pages 1693-1699

  Levine, John E ^a   Logan, Brent ^b   Wu, Juan ^c   Alousi, Amin M ^d   Ho, Vincent ^e   Bolaños Meade, Javier ^f   Weisdorf, Daniel ^g  

^a UNIVERSITY OF MICHIGAN   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c EMMES CORPORATION   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Allogeneic; BMT; GVHD; Prognosis; Response; Survival

Indexed keywords

DENILEUKIN DIFTITOX; ETANERCEPT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PREDNISONE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REDUCTION; DRUG MEGADOSE; GRAFT SURVIVAL; HUMAN; IMMUNOPROPHYLAXIS; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; MYELOABLATIVE CONDITIONING; NEUTROPHIL COUNT; PHASE 2 CLINICAL TRIAL; PREDICTOR VARIABLE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REDUCED INTENSITY CONDITIONING; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADRENAL CORTEX HORMONES; ADULT; DIPHTHERIA TOXIN; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-2; METHYLPREDNISOLONE; MIDDLE AGED; PENTOSTATIN; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 78149414023     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.05.019     Document Type: Article

References (18)

1. Cahn J.Y., Klein J.P., Lee S.J., et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood 2005, 106:1495-1500.
2. Ram R., Gafter-Gvili A., Yeshurun M., Paul M., Raanani P., Shpilberg O. Prophylaxis regimens for GVHD: systematic review and meta-analysis. Bone Marrow Transplant 2009, 43:643-653.
3. Ferrara J.L., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
4. Chao N.J., Chen B.J. Prophylaxis and treatment of acute graft-versus-host disease. Semin Hematol 2006, 43:32-41.
5. MacMillan M.L., Weisdorf D.J., Wagner J.E., et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002, 8:387-394.
6. Pasquini M.C. Impact of graft-versus-host disease on survival. Best Pract Res Clin Haematol 2008, 21:193-204.
7. Antin J.H., Chen A.R., Couriel D.R., Ho V.T., Nash R.A., Weisdorf D. Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2004, 10:655-668.
8. Alousi A.M., Weisdorf D.J., Logan B.R., et al. Etanercept, mycophenolate, denileukin or pentostatin plus corticosteroids for acute graft vs. host disease: a randomized phase II trial from the BMT CTN. Blood 2009, 114:511-517.
9. Leisenring W.M., Martin P.J., Petersdorf E.W., et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood 2006, 108:749-755.
10. Martin P.J. Study design and endpoints in graft-versus-host disease. Best Pract Res Clin Haematol 2008, 21:357-372.
11. Paczesny S., Krijanovski O.I., Braun T.M., et al. A biomarker panel for acute graft-versus-host disease. Blood 2009, 113:273-278.
12. Paczesny S., Braun T., Levine J.E., et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Translat Med 2010, 2:50-57.
13. Fondi C., Nozzoli C., Benemei S., et al. Increase in FOXP3+ regulatory T cells in GVHD skin biopsies is associated with lower disease severity and treatment response. Biol Blood Marrow Transplant 2009, 15:938-947.
14. Wingard J.R. Fungal infections after bone marrow transplant. Biol Blood Marrow Transplant 1999, 5:55-68.
15. Ljungman P., Perez-Bercoff L., Jonsson J., et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006, 91:78-83.
16. Martin P.J., Carpenter P.A., Sanders J.E., Flowers M.E. Diagnosis and clinical management of chronic graft-versus-host disease. Int J Hematol 2004, 79:221-228.
17. Lee S.J., Vogelsang G., Flowers M.E. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003, 9:215-233.
18. Macmillan ML, Defor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood. [epub ahead of print] DOI 101182/blood-2009-12-258442.